Malignant Pleural Mesothelioma Nodal Status: Where Are We at?
Due to the lack of both prospective trial and high-volume retrospective studies, the management of clinical N+ malignant pleural mesothelioma (MPM) patients remains highly debated. Node positive patients show poor survival compared with node-negative ones; thus, lymph node staging appears crucial in...
Main Authors: | Sara Ricciardi, Francesco Carleo, Massimo O. Jaus, Marco Di Martino, Luigi Carbone, Alberto Ricci, Giuseppe Cardillo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/21/5177 |
Similar Items
-
Single-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma
by: Giuseppe Mangiameli, et al.
Published: (2022-08-01) -
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells
by: Valentina Coccè, et al.
Published: (2021-06-01) -
POSTOPERATIVE SURVIVAL RESULTS OF PATIENTS WITH STAGE I-II MALIGNANT PLEURAL MESOTHELIOMA IN AN ENDEMIC AREA
by: Tayfun Kermenli, et al.
Published: (2020-08-01) -
European guidelines for the management of malignant pleural mesothelioma
by: Eric van Thiel, et al.
Published: (2011-10-01) -
An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
by: Davis A, et al.
Published: (2022-03-01)